Ibio Inc
NASDAQ:IBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
SK Target Group Ltd
HKEX:8427
|
MY |
|
V
|
Vizsla Silver Corp
AMEX:VZLA
|
CA |
|
S
|
Sime Darby Plantation Bhd
KLSE:SIMEPLT
|
MY |
|
Besunyen Holdings Co Ltd
HKEX:926
|
CN |
|
C
|
China Zhenhua Group Science & Technology Co Ltd
SZSE:000733
|
CN |
|
A
|
Al-Razi Medical Company SJSC
SAU:9572
|
SA |
|
C
|
CHTC Helon Co Ltd
SZSE:000677
|
CN |
|
Realord Group Holdings Ltd
HKEX:1196
|
HK |
Ibio Inc
EPS (Diluted)
Ibio Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ibio Inc
NASDAQ:IBIO
|
EPS (Diluted)
$0
|
CAGR 3-Years
83%
|
CAGR 5-Years
58%
|
CAGR 10-Years
46%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Ibio Inc
Glance View
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 105 full-time employees. The company went IPO on 2008-08-18. The firm is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The firm through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The firm operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.
See Also
What is Ibio Inc's EPS (Diluted)?
EPS (Diluted)
-0.8
USD
Based on the financial report for Dec 31, 2025, Ibio Inc's EPS (Diluted) amounts to -0.8 USD.
What is Ibio Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
46%
Over the last year, the EPS (Diluted) growth was 61%. The average annual EPS (Diluted) growth rates for Ibio Inc have been 83% over the past three years , 58% over the past five years , and 46% over the past ten years .
